How do medications such as selective serotonin reuptake inhibitors (SSRIs), serotonin‑norepinephrine reuptake inhibitors (SNRIs), benzodiazepines, buspirone, pregabalin, and propranolol reduce anxiety?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Mechanisms of Anxiolytic Medications

Medications reduce anxiety through distinct neurochemical pathways: SSRIs and SNRIs increase serotonin (and norepinephrine) availability at synapses by blocking reuptake, benzodiazepines enhance GABA-mediated inhibition, buspirone acts as a partial agonist at serotonin 5-HT1A receptors, pregabalin modulates calcium channels to reduce neurotransmitter release, and propranolol blocks peripheral beta-adrenergic receptors to diminish physical anxiety symptoms.

SSRIs and SNRIs: Serotonergic Modulation

SSRIs work by blocking the presynaptic reuptake pump for serotonin, increasing its concentration in the synaptic cleft 1. This sustained blockade triggers a cascade: over time, inhibitory serotonin autoreceptors downregulate, which increases serotonergic neuronal firing rates and ultimately enhances serotonin release 1. This multi-step process explains the 2-4 week delay before therapeutic effects emerge 1.

SNRIs function similarly but block reuptake of both serotonin and norepinephrine 2. The dual mechanism provides comparable efficacy to SSRIs across anxiety disorders 3. Venlafaxine shows 30-fold selectivity for serotonin over norepinephrine, while duloxetine has 10-fold selectivity 2. Both SSRIs and SNRIs demonstrated high treatment response rates (NNT = 4.70 for SSRIs, NNT = 4.94 for SNRIs) with dropout rates similar to placebo 3.

Key clinical point: Serotonergic function modulates the brain's ability to process fear, worry, and stress—the core pathophysiology of anxiety disorders 1.

Benzodiazepines: GABAergic Enhancement

Benzodiazepines enhance the effect of gamma-aminobutyric acid (GABA), the brain's primary inhibitory neurotransmitter 3. Unlike SSRIs, they provide rapid anxiolysis but lack evidence from adequately controlled trials for most anxiety disorders 3. The 2023 Japanese guidelines explicitly state that benzodiazepines "have not been adequately studied" and are not included in treatment recommendations 3.

Critical caveat: While benzodiazepines work quickly, they carry risks of dependence, abuse potential, and adverse effects that limit their role, particularly in older adults 4.

Buspirone: Serotonin Receptor Modulation

Buspirone operates through a fundamentally different mechanism than SSRIs. It acts as a partial agonist at serotonin 5-HT1A receptors with high affinity 5. Importantly, buspirone has no significant affinity for benzodiazepine receptors and does not affect GABA binding 5. It also shows moderate affinity for brain D2-dopamine receptors and may have indirect effects on other neurotransmitter systems 5.

Unlike benzodiazepines, buspirone lacks anticonvulsant and muscle relaxant effects and does not produce prominent sedation 5. However, pediatric trials showed no efficacy for buspirone in anxiety disorders 6, and evidence in adults remains limited compared to SSRIs/SNRIs.

Pregabalin: Calcium Channel Modulation

Pregabalin (and gabapentin) modulate voltage-gated calcium channels, reducing the release of excitatory neurotransmitters 7. Pregabalin has the most robust evidence among anticonvulsants for generalized anxiety disorder, with rapid anxiety reduction and a safe side effect profile 7. It represents a viable alternative when SSRIs/SNRIs are ineffective or poorly tolerated.

Propranolol: Peripheral Beta-Blockade

Propranolol blocks beta-adrenergic receptors peripherally, reducing the physical manifestations of anxiety (tremor, tachycardia, sweating) 3. This mechanism addresses somatic symptoms rather than the central cognitive/emotional components of anxiety. Evidence for beta-blockers in anxiety disorders remains limited, and they are not included in guideline recommendations 3.

Comparative Efficacy and Clinical Selection

SSRIs remain first-line pharmacotherapy based on 26 RCTs demonstrating efficacy with favorable tolerability 3. SNRIs (specifically venlafaxine) represent an equivalent first-line option based on 5 RCTs 3. Both classes showed similar dropout rates to placebo, indicating good safety profiles 3.

The 2023 guidelines provide weak recommendations (GRADE 2C) for both SSRIs and SNRIs due to low certainty of evidence, but the benefit-harm balance favors their use 3. Sertraline and escitalopram are preferred SSRIs in older adults 4, while buspirone may be considered when avoiding sexual side effects is a priority in relatively healthy older patients 4.

Common pitfall: Clinicians must counsel patients about the delayed onset of SSRI/SNRI effects (2-4 weeks) to prevent premature discontinuation 1. Additionally, SSRIs/SNRIs require caution regarding serious adverse reactions including serotonin syndrome and neuroleptic malignant syndrome 3.

References

1
Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

6
Research

Advances in Pharmacotherapy for Pediatric Anxiety Disorders.

Child and adolescent psychiatric clinics of North America, 2023

7
Research

Non-Antidepressant Treatment of Generalized Anxiety Disorder.

Current clinical pharmacology, 2015

Related Questions

In an adult patient with anxiety and no contraindications, is propranolol or clonidine preferred as first‑line pharmacologic therapy?
What is the optimal medication management for a 65-year-old woman with persistent anxiety who is currently taking buspirone 5 mg twice daily, citalopram 40 mg daily, atomoxetine (Strattera) 80 mg, and hydroxyzine 10 mg as needed?
What pharmacologic treatment is recommended for anxiety when buspirone and hydroxyzine have been ineffective?
What medication options are appropriate for an adult with generalized anxiety disorder without contraindicating medical conditions?
What is the next anti-anxiety medication option for a patient on Cymbalta (duloxetine) who has not responded to Selective Serotonin Reuptake Inhibitors (SSRIs) and Buspar (buspirone)?
What is the recommended emergency department workup for an infant (<12 months) presenting with a brief resolved unexplained event (BRUE) in the pediatric emergency setting?
What adverse effects should be monitored in hospitalized patients receiving the combination of guaifenesin and dextromethorphan?
What is the mode of transmission of Legionella (Legionella pneumophila) on cruise ships?
How do guaifenesin and dextromethorphan help relieve post‑nasal drip?
What is the appropriate management for a 4‑day‑old neonate with severe unconjugated hyperbilirubinemia (total bilirubin 30.9 mg/dL) and markedly elevated transaminases (AST 127 U/L, ALT 120 U/L)?
How should ventriculomegaly be managed in the emergency department?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.